Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD22/anti-CD28 bispecific antibody REGN5837

A hinge-stabilized human immunoglobulin G4 (IgG4) bispecific antibody directed against both the tumor-associated antigen (TAA) CD22 and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD22/anti-CD28 bispecific antibody REGN5837 targets and binds to both CD28 expressed on T cells and CD22 expressed on tumor cells, which crosslinks the T cells to the tumor cells. This may result in the activation of a cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor cells. CD22 is exclusively expressed on B cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD22 x anti-CD28 costimulatory bispecific monoclonal antibody REGN5837
anti-CD22/CD28 bispecific antibody REGN5837
Code name:CD22xCD28 antibody REGN5837
REGN 5837
REGN-5837
REGN5837
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search